How The Investment Story For Alcidion Group (ASX:ALC) Is Shifting Around A$0.14 Fair Value

Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million individual investors worldwide.

The fair value for Alcidion Group is held at A$0.1425 per share, with no shift in the central price target despite small tweaks elsewhere in the model. Recent sector research on larger medical technology peers, which includes a mix of bullish and cautious signals on product cycles, cash generation and valuation, is feeding into how analysts think about what could support or pressure that A$0.14 per share anchor. As you read on, you will see how these moving parts shape the evolving narrative investors are watching.

Analyst Price Targets don’t always capture the full story. Head over to our Company Report to find new ways to value Alcidion Group.

BTIG highlights product cadence and profitability as being on steady footing, while also pointing to strong free cash flow that gives larger medtech peers scope for M&A and buybacks, which can shape how investors think about balance sheet flexibility for smaller names like Alcidion Group.
Wells Fargo, Barclays and Stifel all discuss new product cycles and portfolio bright spots at Alcon, using higher price targets as a signal that, when execution on launches is solid, markets can support higher valuation anchors for health technology companies.
BTIG also frames recent sector Q4 reporting as supportive for companies that can pair consistent cash generation with measured growth expectations, a mix that underpins how some investors may assess the A$0.1425 per share fair value for Alcidion Group.

BTIG explicitly flags that outperformance in ophthalmic names hinges on end market conditions, reminding investors that even with healthy product pipelines, sector valuations can be sensitive to softer procedure volumes and more cautious outlooks.
Price target cuts at firms like Berenberg, along with Neutral or Equal Weight views from William Blair and others on Alcon, show that some analysts remain careful on medtech valuation, which can act as a cap on how far investors are willing to stretch multiples for smaller health tech stocks such as Alcidion Group.

Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there’s more to the story. Head to the Simply Wall St Community to discover more perspectives!

See how Alcidion Group’s fair value stacks up across multiple valuation models — not just analyst targets.

Alcidion Group is reviewing potential M&A opportunities, and management indicated that any transaction would be assessed against the company’s three existing growth pillars.
The company reaffirmed fiscal 2026 guidance, stating that it expects revenue to exceed A$50.0 million.
As at 31 December 2025, Alcidion reported contracted revenue for fiscal 2026 of A$43.1 million from sold and renewal contracts, described as 40% above the prior corresponding period and 6% above fiscal 2025 full year revenue.

Fair value is held at A$0.1425 per share, with no movement in the central valuation anchor.
Revenue growth is retained at around 4.33%, with no change to the implied A$ revenue growth outlook in the model.
Net profit margin is held effectively steady at about 6.19%, with no shift in expected earnings efficiency.
Future P/E is adjusted marginally from 70.58x to 70.60x, reflecting a very small change in the multiple applied to future earnings.
The discount rate is set at 8.06%, reflecting only a marginal recalibration in risk assumptions.

Narratives link a company’s real world story to a financial forecast and fair value, so you can see how contracts, guidance and risks fit together. They also refresh as new data, guidance and sector research come through.

Head over to the Simply Wall St Community and follow the Narrative on Alcidion Group to stay up to date on:

How growth in annual recurring revenue, multi year modular contracts and the Miya Precision platform relate to revenue visibility and recurring earnings.
What expansion into markets such as the UK, Canada, Saudi Arabia and the UAE, together with a land and expand sales approach, could mean for contract sizes and diversification.
Key risks from UK revenue concentration, dependence on a small number of large contracts and the execution and cost pressures associated with international expansion and regulation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ALC.AX.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

Source link